NEPH
Nephros, Inc.4.8500
-0.0100-0.21%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
51.54MP/E (TTM)
34.64Basic EPS (TTM)
0.14Dividend Yield
0%Recent Filings
8-K
New Medica deal signed
Nephros inked a new license and supply agreement with Medica on November 21, 2025, replacing their 2023 pact, granting exclusive rights to market ultrafiltration Products in the defined Territory through 2030. Nephros commits to minimum annual purchases escalating from €4,976,000 in 2026 to €6,300,000 in 2030. New deal locks in supply. Termination risks hinge on monetary defaults or uncured breaches.
10-Q
Q3 FY2025 results
Nephros posted Q3 revenue of $4.8M, up 35% y/y from $3.5M, with gross margin steady at 61%; YTD revenue hit $14.1M, up 37% y/y, lifting gross margin to 63% and flipping operating income to $1.1M from a $0.3M loss. Product revenue drove the surge, fueled by strong reorders and new sites, while service revenue jumped. Cash swelled to $5.2M on $1.4M operating cash flow (capex nil, so FCF matches). No debt weighs the balance sheet. Diluted EPS of $0.10 reconciles cleanly to YTD net income on 10.8M shares. Revenue hinges on a few big customers.
8-K
Q2 revenue up 36%
Nephros reported Q2 net revenue of $4.4 million, up 36% from $3.3 million last year, with net income of $237,000 versus a $289,000 loss. Gross margins expanded to 63% from 59% on lower shipping costs and inventory adjustments, while programmatic sales hit record highs. Third straight profitable quarter. Cash climbed to $5.1 million, debt-free.
10-Q
Q2 FY2025 results
Nephros flipped to profitability in Q2 FY2025 ended June 30, 2025, posting $4.4M revenue (up 36% y/y), $0.8M operating income (vs $0.3M loss), and $0.02 diluted EPS on 10.8M shares—reconciles cleanly. Gross margins expanded to 63% from 59% y/y on lower shipping costs and fewer inventory reserves, while product revenue jumped to $4.3M (up 34% y/y). YTD revenue hit $9.3M (up 37% y/y), with $1.3M operating cash flow (no capex disclosed). Cash swelled to $5.1M, debt-free save minor leases. Two customers drove 39% of Q2 sales. Customer concentration lingers.
8-K
Annual meeting votes pass
Nephros stockholders at the June 16, 2025 Annual Meeting elected Lisa Nettis to the board for a three-year term expiring 2028, with 6,066,124 for and 84,178 withheld. They ratified Baker Tilly US as auditors for fiscal 2025, passing overwhelmingly at 8,663,982 for. Say-on-pay won handily too. Routine governance locked in.
IPO
Website
Employees
Sector
Industry
AVNS
Avanos Medical, Inc.
11.62-0.24
AVTR
Avantor, Inc.
11.20-0.08
MMSI
Merit Medical Systems, Inc.
86.85+0.44
NSYS
Nortech Systems Incorporated
7.17+0.18
NUWE
Nuwellis, Inc.
2.21+0.03
NXGL
NexGel, Inc
1.64+0.05
OM
Outset Medical, Inc.
3.92-0.05
UEEC
United Health Products, Inc.
0.06+0.00
UTMD
Utah Medical Products, Inc.
58.43+0.94
WTER
Alkaline Water Company Inc. (Th
0.12+0.11